7:18

Key Insights: Leukemia & Myeloid Disorders

HMP Education

16:26

Debate: Is CR and MRD negativity still required in the era of novel agents? - No

HMP Education

29:15

Clinical considerations for the use of oral targeted therapies in CLL

HMP Education

15:23

Debate: Optimal approach for the management of CLL patients with del(17p) - Ibrutinib

HMP Education

13:55

Debate: Optimal approach for the management of CLL patients with del(17p) - Novel Agents

HMP Education

30:14

When can TKIs be stopped in CML?

HMP Education

21:14

CML molecular monitoring: Practical advice

HMP Education

24:18

Atypical CML: Diagnosis and management

HMP Education

23:51

Reversal of newer anticoagulants – When and how

HMP Education

23:28

Diagnosis and management of Hemophagocytic lymphohistiocytosis (HLH)

HMP Education

24:52

Combination Therapy with JAK2 inhibitors in MPN

HMP Education

25:52

Management of CMML

HMP Education

20:13

Debate: Hypomethylating agents are appropriate in lower-risk MDS - Only Use With Caution

HMP Education

25:20

Promise and pitfalls in molecular testing in the diagnosis of MDS

HMP Education